Cost-effectiveness analysis of asymptomatic peripheral artery disease screening with the ABI test

Nathan K. Itoga, Hataka R. Minami, Meenadachi Chelvakumar, Keon Pearson, Matthew Mell, Eran Bendavid, Douglas K. Owens

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Screening for asymptomatic peripheral artery disease (aPAD) with the ankle–brachial index (ABI) test is hypothesized to reduce disease progression and cardiovascular (CV) events by identifying individuals who may benefit from early initiation of medical therapy. Using a Markov model, we evaluated the cost effectiveness of initiating medical therapy (e.g. statin and ACE-inhibitor) after a positive ankle–brachial index (ABI) screen in 65-year-old patients. We modeled progression to symptomatic PAD (sPAD) and CV events with and without ABI screening, evaluating differences in costs and quality-adjusted life years (QALYs). The cost of the ABI test, physician visit, new medication, CV events, and interventions for sPAD were incorporated in the model. We performed sensitivity analysis on model variables with uncertainty. Our model found an incremental cost of US $338 and an incremental QALY of 0.00380 with one-time ABI screening, resulting in an incremental cost-effectiveness ratio (ICER) of $88,758/QALY over a 35-year period. The variables with the largest effects in the ICER were aPAD disease prevalence, cost of monthly medication after a positive screen and 2-year medication adherence rates. Screening high-risk populations, such as tobacco users, where the prevalence of PAD may be 2.5 times higher, decreases the ICER to $24,092/QALY. Our analysis indicates the cost effectiveness of one-time screening for aPAD depends on prevalence, medication costs, and adherence to therapies for CV disease risk reduction. Screening in higher-risk populations under favorable assumptions about medication adherence results in the most favorable cost effectiveness, but limitations in the primary data preclude definitive assessment of cost effectiveness.

Original languageEnglish (US)
Pages (from-to)97-106
Number of pages10
JournalVascular Medicine (United Kingdom)
Volume23
Issue number2
DOIs
StatePublished - Apr 1 2018
Externally publishedYes

Fingerprint

Peripheral Arterial Disease
Cost-Benefit Analysis
Quality-Adjusted Life Years
Medication Adherence
Costs and Cost Analysis
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cost of Illness
Risk Reduction Behavior
Angiotensin-Converting Enzyme Inhibitors
Population
Uncertainty
Tobacco
Disease Progression
Cardiovascular Diseases
Therapeutics
Physicians

Keywords

  • ankle–brachial index (ABI)
  • cardiovascular disease
  • peripheral artery disease (PAD)
  • screening

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cost-effectiveness analysis of asymptomatic peripheral artery disease screening with the ABI test. / Itoga, Nathan K.; Minami, Hataka R.; Chelvakumar, Meenadachi; Pearson, Keon; Mell, Matthew; Bendavid, Eran; Owens, Douglas K.

In: Vascular Medicine (United Kingdom), Vol. 23, No. 2, 01.04.2018, p. 97-106.

Research output: Contribution to journalArticle

Itoga, Nathan K. ; Minami, Hataka R. ; Chelvakumar, Meenadachi ; Pearson, Keon ; Mell, Matthew ; Bendavid, Eran ; Owens, Douglas K. / Cost-effectiveness analysis of asymptomatic peripheral artery disease screening with the ABI test. In: Vascular Medicine (United Kingdom). 2018 ; Vol. 23, No. 2. pp. 97-106.
@article{c18be26000c645f7ba1186fc67ad4432,
title = "Cost-effectiveness analysis of asymptomatic peripheral artery disease screening with the ABI test",
abstract = "Screening for asymptomatic peripheral artery disease (aPAD) with the ankle–brachial index (ABI) test is hypothesized to reduce disease progression and cardiovascular (CV) events by identifying individuals who may benefit from early initiation of medical therapy. Using a Markov model, we evaluated the cost effectiveness of initiating medical therapy (e.g. statin and ACE-inhibitor) after a positive ankle–brachial index (ABI) screen in 65-year-old patients. We modeled progression to symptomatic PAD (sPAD) and CV events with and without ABI screening, evaluating differences in costs and quality-adjusted life years (QALYs). The cost of the ABI test, physician visit, new medication, CV events, and interventions for sPAD were incorporated in the model. We performed sensitivity analysis on model variables with uncertainty. Our model found an incremental cost of US $338 and an incremental QALY of 0.00380 with one-time ABI screening, resulting in an incremental cost-effectiveness ratio (ICER) of $88,758/QALY over a 35-year period. The variables with the largest effects in the ICER were aPAD disease prevalence, cost of monthly medication after a positive screen and 2-year medication adherence rates. Screening high-risk populations, such as tobacco users, where the prevalence of PAD may be 2.5 times higher, decreases the ICER to $24,092/QALY. Our analysis indicates the cost effectiveness of one-time screening for aPAD depends on prevalence, medication costs, and adherence to therapies for CV disease risk reduction. Screening in higher-risk populations under favorable assumptions about medication adherence results in the most favorable cost effectiveness, but limitations in the primary data preclude definitive assessment of cost effectiveness.",
keywords = "ankle–brachial index (ABI), cardiovascular disease, peripheral artery disease (PAD), screening",
author = "Itoga, {Nathan K.} and Minami, {Hataka R.} and Meenadachi Chelvakumar and Keon Pearson and Matthew Mell and Eran Bendavid and Owens, {Douglas K.}",
year = "2018",
month = "4",
day = "1",
doi = "10.1177/1358863X17745371",
language = "English (US)",
volume = "23",
pages = "97--106",
journal = "Vascular Medicine (United Kingdom)",
issn = "1358-863X",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - Cost-effectiveness analysis of asymptomatic peripheral artery disease screening with the ABI test

AU - Itoga, Nathan K.

AU - Minami, Hataka R.

AU - Chelvakumar, Meenadachi

AU - Pearson, Keon

AU - Mell, Matthew

AU - Bendavid, Eran

AU - Owens, Douglas K.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Screening for asymptomatic peripheral artery disease (aPAD) with the ankle–brachial index (ABI) test is hypothesized to reduce disease progression and cardiovascular (CV) events by identifying individuals who may benefit from early initiation of medical therapy. Using a Markov model, we evaluated the cost effectiveness of initiating medical therapy (e.g. statin and ACE-inhibitor) after a positive ankle–brachial index (ABI) screen in 65-year-old patients. We modeled progression to symptomatic PAD (sPAD) and CV events with and without ABI screening, evaluating differences in costs and quality-adjusted life years (QALYs). The cost of the ABI test, physician visit, new medication, CV events, and interventions for sPAD were incorporated in the model. We performed sensitivity analysis on model variables with uncertainty. Our model found an incremental cost of US $338 and an incremental QALY of 0.00380 with one-time ABI screening, resulting in an incremental cost-effectiveness ratio (ICER) of $88,758/QALY over a 35-year period. The variables with the largest effects in the ICER were aPAD disease prevalence, cost of monthly medication after a positive screen and 2-year medication adherence rates. Screening high-risk populations, such as tobacco users, where the prevalence of PAD may be 2.5 times higher, decreases the ICER to $24,092/QALY. Our analysis indicates the cost effectiveness of one-time screening for aPAD depends on prevalence, medication costs, and adherence to therapies for CV disease risk reduction. Screening in higher-risk populations under favorable assumptions about medication adherence results in the most favorable cost effectiveness, but limitations in the primary data preclude definitive assessment of cost effectiveness.

AB - Screening for asymptomatic peripheral artery disease (aPAD) with the ankle–brachial index (ABI) test is hypothesized to reduce disease progression and cardiovascular (CV) events by identifying individuals who may benefit from early initiation of medical therapy. Using a Markov model, we evaluated the cost effectiveness of initiating medical therapy (e.g. statin and ACE-inhibitor) after a positive ankle–brachial index (ABI) screen in 65-year-old patients. We modeled progression to symptomatic PAD (sPAD) and CV events with and without ABI screening, evaluating differences in costs and quality-adjusted life years (QALYs). The cost of the ABI test, physician visit, new medication, CV events, and interventions for sPAD were incorporated in the model. We performed sensitivity analysis on model variables with uncertainty. Our model found an incremental cost of US $338 and an incremental QALY of 0.00380 with one-time ABI screening, resulting in an incremental cost-effectiveness ratio (ICER) of $88,758/QALY over a 35-year period. The variables with the largest effects in the ICER were aPAD disease prevalence, cost of monthly medication after a positive screen and 2-year medication adherence rates. Screening high-risk populations, such as tobacco users, where the prevalence of PAD may be 2.5 times higher, decreases the ICER to $24,092/QALY. Our analysis indicates the cost effectiveness of one-time screening for aPAD depends on prevalence, medication costs, and adherence to therapies for CV disease risk reduction. Screening in higher-risk populations under favorable assumptions about medication adherence results in the most favorable cost effectiveness, but limitations in the primary data preclude definitive assessment of cost effectiveness.

KW - ankle–brachial index (ABI)

KW - cardiovascular disease

KW - peripheral artery disease (PAD)

KW - screening

UR - http://www.scopus.com/inward/record.url?scp=85045346176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045346176&partnerID=8YFLogxK

U2 - 10.1177/1358863X17745371

DO - 10.1177/1358863X17745371

M3 - Article

C2 - 29345540

AN - SCOPUS:85045346176

VL - 23

SP - 97

EP - 106

JO - Vascular Medicine (United Kingdom)

JF - Vascular Medicine (United Kingdom)

SN - 1358-863X

IS - 2

ER -